Safety Evaluation of Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-DOTA0-Tyr3-Octreotate for Refractory or Recurrent Metastatic Neuroblastoma Expressing Somatostatin Receptors
Condition: Neuroblastoma Intervention: Drug: PRRT with 177Lu-DOTATATE Sponsor: Institut Claudius Regaud Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials